AG
SLRN

Artal Group’s ACELYRIN SLRN Stock Holding History

Artal Group’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,020,888
Closed -$8.91M – 86
2024
Q2 		$8.91M Sell
2,020,888
-384,255
-16% -$1.8M 0.23% 42
2024
Q1 		$16.2M Sell
2,405,143
-630,745
-21% -$4.79M 0.42% 31
2023
Q4 		$22.6M Buy
3,035,888
+566,609
+23% +$4.84M 0.77% 20
2023
Q3 		$25.1M Buy
2,469,279
+648,065
+36% +$13.8M 1.09% 15
2023
Q2 		$38.1M Buy
+1,821,214
New +$37.2M 1.22% 16

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return